News

Goldman Sachs Shows Strong Growth: A Delight for Investors

Goldman Sachs Shows Strong Growth: A Delight for Investors

Goldman Sachs Exceeds Earnings Expectations

Goldman Sachs has once again delivered a stellar performance that has impressed analysts and investors alike. The investment banking powerhouse recently reported third-quarter earnings that significantly surpassed market expectations, leading to a 3.3% rise in its stock in early trading.

Remarkable Earnings Per Share Reported

For the quarter ending September 30, 2024, the company announced adjusted earnings per share of $8.40. This figure notably eclipsed the analyst consensus of $6.93. In addition, Goldman Sachs reported revenue of $12.7 billion, exceeding expectations of $11.81 billion. This marks a remarkable 7% increase compared to the same period last year, highlighting the firm’s ongoing growth and resilience.

Key Drivers of Strong Revenue Growth

The Global Banking & Markets division played a pivotal role in driving this impressive performance. It generated quarterly net revenues amounting to $8.55 billion. This segment showcased excellent results, particularly in Equities, while also achieving record revenues in Fixed Income, Currency, and Commodities financing. The strong performance in these areas underscores Goldman Sachs' ability to navigate a complex financial landscape successfully.

Leadership's Commitment to Growth

David Solomon, the Chairman and CEO of Goldman Sachs, remarked on the company's strong performance, stating, "Our performance demonstrates the strength of our world-class franchise in an improving operating environment." He attributed this success to the firm's exceptional talent, execution capabilities, and risk management expertise, which have enabled the company to effectively cater to client needs.

Asset & Wealth Management Contributions

Asset & Wealth Management also had a significant impact on the overall positive results, contributing quarterly revenues of $3.75 billion, which included record Management and other fees. Notably, assets under supervision rose by $169 billion, reaching an impressive total of $3.10 trillion during this quarter. This growth reflects the firm’s ability to manage and grow client assets successfully.

Dominance in Investment Banking

Goldman Sachs maintains its leading position in investment banking, consistently ranking first in worldwide announced and completed mergers and acquisitions, as well as common stock offerings for the year to date. The firm's investment banking fees increased by 20%, totaling $1.87 billion, showcasing its dominance in this critical sector of the financial market.

Financial Stability and Growth Metrics

Regarding credit risks, Goldman Sachs reported a provision for credit losses of $397 million for the third quarter of 2024, a sharp increase from $7 million for the same quarter in the previous year and $282 million for the preceding quarter. This provision indicates the company's proactive approach to managing its credit risks in a changing economic environment.

Furthermore, Goldman Sachs' book value per common share rose by 1.8% during the quarter, now standing at $332.96. The company’s annualized return on average common shareholders' equity (ROE) was reported at 10.4% for the third quarter, indicating solid profitability and efficient capital management.

Frequently Asked Questions

What were the earnings per share for Goldman Sachs in Q3 2024?

Goldman Sachs reported adjusted earnings per share of $8.40 for the third quarter of 2024.

How much revenue did Goldman Sachs generate in Q3 2024?

The firm generated revenue of $12.7 billion in the third quarter of 2024.

What drove the strong performance of Goldman Sachs in Q3?

The Global Banking & Markets division was a key driver, along with contributions from Asset & Wealth Management.

What is the current book value per common share for Goldman Sachs?

The book value per common share increased to $332.96 during the quarter.

How did Goldman Sachs perform in terms of investment banking fees?

Investment banking fees rose by 20% to reach $1.87 billion, securing Goldman's leading position in the sector.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading